drugset
drugset / Trial / NCT03374007

Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma

NCT03374007 ↗

Phase 1 Unknown 72 enrolled Genor Biopharma Co., Ltd.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

With open, single/ multiple dosing and dose escalation, phase I clinical trial scheme to evaluate safety, tolerance and pharmacokinetic properties of Genolimzumab injection in Chinese patients of advanced and (or) recurrent solid tumor/lymphoma

Timeline

Start
2017-10-19
Primary completion
2022-06
Completion
2022-08

Drugs

EvaluationDrugModalityDoseRoute
Subject APL-501 Monoclonal antibody 1 mg/kg Intravenous
Subject APL-501 Monoclonal antibody 3 mg/kg Intravenous
Subject APL-501 Monoclonal antibody 10 mg/kg Intravenous
Subject APL-501 Monoclonal antibody 280 mg Intravenous

Indications

Hodgkin's lymphoma, lymphocytic depletion